Gene · 970
NIH grants2,135
NIH grants whose papers are about the gene, through NIH's grant-paper links.
501 to 520 of 2,135
Download this page as JSON| Grant | Title | CD70 papers | Newest fiscal year |
|---|---|---|---|
| R01CA168814 | Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease | 1 | 2024 |
| R01CA234183 | Therapeutic strategies against EGFR exon 20 mutant lung cancer | 1 | 2024 |
| R01CA235159 | TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma | 1 | 2024 |
| R01CA235622 | Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen | 1 | 2024 |
| R01CA236910 | Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance | 1 | 2024 |
| R01CA238514 | Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment | 1 | 2024 |
| R01CA242020 | Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia | 1 | 2024 |
| R01CA242069 | Role of the stromal microenvironment in B-cell lymphoma progression and immune escape | 1 | 2024 |
| R01CA242845 | Blocking tumor progression in therapy-responsive RET aberration-associated cancer | 1 | 2024 |
| R01CA244212 | The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma | 1 | 2024 |
| R01CA244281 | Elucidating the Role of UCHL1 in Aggressive Prostate Cancer | 1 | 2024 |
| R01CA244327 | Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics | 1 | 2024 |
| R01CA246716 | Drug-Free Macromolecular Therapeutics | 1 | 2024 |
| R01CA246785 | Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors | 1 | 2024 |
| R01CA247471 | Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer | 1 | 2024 |
| R01CA247975 | Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors | 1 | 2024 |
| R01CA248736 | ITIM-receptors for cancer treatment | 1 | 2024 |
| R01CA251138 | Interrogating the minor spliceosome to understand and treat leukemia | 1 | 2024 |
| R01CA252937 | Tumor matrix remodeling in anti-myeloma immunity and immunotherapy | 1 | 2024 |
| R01CA252940 | Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/grants?page=26